Clinical translational analysis revealed that Csrp2 demonstrates superior diagnostic efficacy (AUC >0.8) in HCC tissues compared to conventional biomarker AFP, with its peripheral blood detection technology showing promise for non-invasive early screening of liver cancer. Here, CSRP2 is linked to hepatocellular carcinoma.